FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on June 15, 2023, to discuss and make recommendations for SARS-CoV-2 strain(s) for updated COVID-19 vaccines for use in the United States beginning in the fall of 2023.
The committee unanimously voted that the vaccine composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant for the 2023-2024 formulation of the COVID-19 vaccines for use beginning this fall.
“Based on the totality of the evidence, FDA has advised manufacturers who will be updating their COVID-19 vaccines that they should develop vaccines with a monovalent XBB 1.5 composition.”
